弥漫性大 B 细胞睾丸淋巴瘤中 MAGE-A 和 NY-ESO-1 癌/睾丸抗原的免疫组织化学分析。
Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma.
机构信息
Department of Urology, Zagreb University Hospital Center, Zagreb, Croatia.
出版信息
J Transl Med. 2013 May 16;11:123. doi: 10.1186/1479-5876-11-123.
BACKGROUND
Primary testicular lymphoma (PTL) is a rare and lethal disease. The most common histological subtype is diffuse large B-cell lymphoma (DLBCL). Standard treatments are frequently ineffective. Thus, the development of novel forms of therapy is urgently required. Specific immunotherapy generating immune responses directed against antigen predominantly expressed by cancer cells such as cancer-testis antigens (CTA) may provide a valid alternative treatment for patients bearing PTL, alone or in combination with current therapies.
METHODS
Three monoclonal antibodies (mAbs), 77B recognizing MAGE-A1, 57B recognizing an epitope shared by multiple MAGE-A CTA (multi-MAGE-A specific) and D8.38 recognizing NY-ESO-1/LAGE-1 were used for immunohistochemical staining of 27 PTL, including 24 DLBCL.
RESULTS
Expression of MAGE-A1 was infrequently detectable in DLBCL specimens (12.50%), whereas multi-MAGE-A and NY-ESO-1/LAGE-1 specific reagents stained the cytoplasms of tumor cells in DLBCL specimens with higher frequencies (54.17% and 37.50%, respectively) with different expression levels.
CONCLUSIONS
These results suggest that MAGE-A and NY-ESO-1/LAGE-1, possibly in combination with other CTA, might be used as targets for specific immunotherapy in DLBCL.
背景
原发性睾丸淋巴瘤（PTL）是一种罕见且致命的疾病。最常见的组织学亚型是弥漫性大 B 细胞淋巴瘤（DLBCL）。标准治疗通常无效。因此，迫切需要开发新的治疗形式。针对主要由癌细胞表达的抗原（如癌症睾丸抗原（CTA））产生免疫反应的特异性免疫疗法，可能为患有 PTL 的患者提供一种有效的替代治疗方法，单独或与当前疗法联合使用。
方法
三种单克隆抗体（mAbs），77B 识别 MAGE-A1，57B 识别多个 MAGE-A CTA（多-MAGE-A 特异性）和 D8.38 识别 NY-ESO-1/LAGE-1，用于对 27 例 PTL 进行免疫组织化学染色，包括 24 例 DLBCL。
结果
MAGE-A1 在 DLBCL 标本中的表达频率较低（12.50%），而多-MAGE-A 和 NY-ESO-1/LAGE-1 特异性试剂以不同的表达水平更高频率地染色 DLBCL 标本中的肿瘤细胞质（分别为 54.17%和 37.50%）。
结论
这些结果表明，MAGE-A 和 NY-ESO-1/LAGE-1，可能与其他 CTA 一起，可作为 DLBCL 特异性免疫治疗的靶点。
Zotero 插件